BiBBInstruments

BiBB issued a total of 2,755,282 warrants of series TO 1 in connection with the Company's rights issue of units that was completed during the first quarter of 2025. In accordance with the terms for the Warrants, the holders are entitled, during the period from and including May 22, 2025 until and including June 5, 2025, to subscribe for one (1) new share in BiBB for each (1) Warrant held. The subscription price for shares subscribed for through the exercise of TO 1 shall, according to the terms of the Warrants, correspond to 70 percent of the volume-weighted average price for the Company's share on Spotlight Stock Market during the Measurement Period, however, not less than SEK 3.25 and not more than SEK 6.00. The volume-weighted average price of the Company's share on Spotlight Stock Market during the Measurement Period was 3.11 SEK, meaning that the subscription price for the exercise of the Warrants has been set at SEK 3.25 per share.

Complete terms and conditions for the Warrants are available on the Company's website: www.bibbinstruments.com.

Advisors
DNB Carnegie SME and Setterwalls Advokatbyrå AB acted financial and legal advisors to BiBB in connection with the Rights Issue.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

About BiBB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill® GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. Thus EndoDrill® is the first cleared powered endoscopic biopsy system in both the US and Europe. The EndoDrill® system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.